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Abstract 
 
Second generation antipsychotics (SGAs) are effective options in the treatment of schizophrenia and mood 
disorders, each with characteristic efficacy and safety features. In order to optimize the balance between 
efficacy and side effects, it is of upmost importance to match compound specificity against patient clinical 
profile. As the number of SGAs increased, this review can assist physicians in the prescription of three novel 
SGAs already on the market, namely lurasidone, brexpiprazole, cariprazine, and lumateperone, which is in the 
approval phase for schizophrenia treatment at the FDA.  
Besides schizophrenia, EMA and/or FDA approved lurasidone for bipolar depression, brexpiprazole as 
augmentation in major depressive disorder and cariprazine for the acute treatment of manic or mixed episodes 
associated with bipolar I disorder. These new antipsychotics were developed with the aim of improving 
efficacy on negative and depressive symptoms and reducing metabolic and cardiovascular side effects 
compared to prior SGAs, while keeping the risk of extrapyramidal symptoms low. They succeeded quite well 
in containing these side effects, despite weight gain during acute treatment remains a possible concern for 
brexpiprazole, while cariprazine and lurasidone show higher risk of akathisia compared to placebo and other 
SGAs such as olanzapine. The available studies support the expected benefits on negative symptoms, cognitive 
dysfunction and depressive symptoms, while the overall effect on acute psychotic symptoms may be similar 
to other SGAs such as quetiapine, aripiprazole and ziprasidone.  
The discussed new antipsychotics represent useful therapeutic options but their efficacy and side effect profiles 
should be considered to personalize prescription. 
 
 
 
Keywords: Antipsychotics; Brexpiprazole; Cariprazine; Lumateperone; Lurasidone; Personalized Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
1. Introduction 
Second-generation antipsychotics (SGAs) have become the mainstream pharmacological treatment for 
schizophrenia and they are often used as primary therapy or augmentation in affective disorders as well (Taylor 
et al., 2018). SGAs are not a homogeneous pharmaceutical class: each has indeed characteristic side effect 
profiles and specific efficacy domains. Therefore, when prescribing SGAs, best clinical practice requires to 
match compound specificity against the features of different subsets of patients, i.e. disease characteristics and 
vulnerability to side effects (Lally and MacCabe, 2015; Leucht et al., 2009). As new oral SGAs have become 
available over the past decade, a clinically oriented appreciation of the profile of such agents is called for and 
can assist clinicians in prescription. Various agents differ in terms of dosing frequency, need for titration to a 
therapeutic dose, drug-drug interactions, domains of efficacy, commonly encountered adverse effects, domains 
of efficacy and last but not least market price. Recognizing specific pros and cons is therefore of upmost 
importance. The aim of this review is to outline pharmacological properties, efficacy, safety and tolerability 
of new antipsychotics as well as to suggest their specific place in psychiatric pharmacotherapy, in the 
framework of precision medicine. Only adverse effects with incidence ≥ 5% having at least twice the rate of 
placebo are outlined in the present paper, since their broad relevance in clinical practice. The antipsychotics 
of interest are those approved by the U.S. Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) since 2010, i.e. lurasidone, brexpiprazole and cariprazine. Lumateperone, a drug with novel 
mechanism of action, will be also discussed since its Phase III clinical development has been completed and 
the FDA accepted a New Drug Application for lumateperone for the treatment of schizophrenia (Intra-Cellular 
Therapies, 2018).  
 
2. Lurasidone 
 
Lurasidone is approved for the acute and maintenance treatment of schizophrenia (FDA, 2010; EMA, 2014) 
and bipolar I depression in monotherapy or in combination with lithium or valproate (FDA, 2013) (Table 1). 
Distinctive of lurasidone (Table 2) is a potent antagonism at the serotonin 5-HT7 receptor, which, coupled 
with 5-HT1A partial agonism, could potentially be associated with improved cognition and antidepressant 
effects (Ishibashi et al., 2010). Of notice, lurasidone antidepressant effects in preclinical behavioral animal 
models were absent in 5-HT7 knockout mice; such effects therefore appear to be mediated by these receptors 
(Cates et al., 2013). Lurasidone shows high affinity for the 5-HT2A and dopamine D2 receptors - the latter is 
associated with extrapyramidal symptoms (EPS) - and low affinity for the M1, H1, 5-HT2C and alpha1 
receptors, suggesting a low liability to cause peripheral and central anticholinergic side effects, somnolence, 
weight gain and hypotension.  
Dosing instructions recommend to take lurasidone once daily in the evening, to reduce the incidence of EPS 
and sedation. Furthermore, a meal with the caloric value of at least 350 kcal, regardless of the fat content, 
should accompany lurasidone administration, considering that it optimizes lurasidone exposure acting on 
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relevant pharmacokinetic parameters (two- to three-fold compared to fasting conditions)[FC1] (Preskorn et al., 
2013).  
 
2.1 Schizophrenia 
 
Five trials demonstrated lurasidone efficacy in acute schizophrenia (Loebel et al., 2013a; Meltzer et al., 2011; 
Nakamura et al., 2009; Nasrallah et al., 2013; Ogasa et al., 2013). No titration is needed to reach the minimum 
effective dose (40 mg/day). However, a dose-dependent efficacy gradient across the approved dose range (US: 
40-160 mg/day; the equivalent in the EU: 37-148 mg/day) seemingly exists: pooling data from short-term 
studies, the number needed to treat (NNT) of lurasidone (versus placebo) (Table 3) for a ≥ 30% reduction in 
the positive and negative syndrome scale (PANSS) (Kay et al., 1987) total score was 4 (95% CI 3-5) at 160 
mg/day as opposed to 6 (95% CI 5-10) at 40 mg/day (Citrome, 2012). In case of early non-response (< 20% 
PANSS total score improvement at week 2), dose escalation to 160 mg/day is a safe and efficacious strategy 
(Loebel et al., 2016). Dose increases are recommended with increments of 40 mg at approximately weekly 
intervals. A pooled analysis of short-term trials showed that lurasidone significantly improved each of the five 
PANSS factor scores in a dose-dependent fashion, albeit not completely linear (Loebel et al., 2015). However, 
in comparison to other SGAs, the scale of lurasidone overall impact appears modest: in a meta-analysis of 15 
SGAs (Leucht et al., 2013), it ranked in the bottom half for PANSS total improvement in acute schizophrenia. 
Lurasidone was suggested to have higher effect size on symptom improvement when positive symptoms are 
prominent compared to cases without prominent positive symptoms (Potkin et al., 2016). A recent meta-
analysis comparing lurasidone and brexpiprazole found that the two had similar efficacy (Ng-Mak et al., 2018). 
Lurasidone tackled severe cases of agitation (NNT of 8 (95% CI 5-17) for a ≥ 40% reduction in the PANSS-
excited component (PANSS-EC)), while improvement was not significantly greater than placebo in patients 
with lower levels of agitation at baseline. The magnitude of improvement in agitation increased at higher doses 
of lurasidone, in the range of 120-180 mg/day (Cohen’s d of 0.43 vs. 0.19 for 40-80 mg/day lurasidone)  (Allen 
et al., 2017). Lastly, depressive symptoms of schizophrenia are another domain which lurasidone specifically 
addresses (NNTs ranged from 11 to 14 for response and remission according to the Montgomery–Åsberg 
Depression Rating Scale (MADRS)) (Nasrallah et al., 2015).  
Five studies (Citrome et al., 2012; Citrome et al., 2014b; Loebel et al., 2013b; Stahl et al., 2013; Tandon et al., 
2016) demonstrated that lurasidone is effective as prophylactic treatment in schizophrenia, reducing the risk 
of relapse by 33.7% compared to placebo in a 28-week period. In 6-12 month studies it was showed that 
lurasidone had similar efficacy in preventing recurrence compared to quetiapine XR but it may provide higher 
benefits in terms of symptom reduction, remission and risk of hospitalization or emergency service utilization 
(Loebel et al., 2013b). Moreover, lurasidone improved cognition more than quetiapine XR across all the 
examined cognitive domains (speed of processing, visual learning, working memory, reasoning/problem 
solving and social cognition) (Harvey et al., 2015). This favorable action on cognition was also observed in 
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comparison to ziprasidone in the non-acute phase of schizophrenia or schizoaffective disorder (particularly 
when considering processing speed) (Potkin et al., 2011). 
Lurasidone was well tolerated and a similar side effects profile was recorded over both short and longer term. 
In 6-weeks trials, commonly encountered adverse events from lurasidone were somnolence, akathisia, nausea, 
parkinsonism and insomnia (Sanford, 2013). However, number needed to harm (NNH) values (Table 3) were 
generally in the double digits, reflecting an overall tolerable profile: the 5 most consistently encountered 
adverse events attributable to lurasidone were akathisia, nausea, sedation, somnolence and parkinsonism with 
NNH vs. placebo for lurasidone 40–120 mg/d ranging from 6 (akathisia with 120 mg/d) to 30 (parkinsonism 
with 80 mg/d)  (Citrome, 2012). Akathisia and EPS appear to be dose-related within the dose range of 20–120 
mg/day. Lurasidone was associated with a low risk of hyperprolactinaemia, QTc interval prolongation, weight 
gain and metabolic disturbances. Compared to olanzapine and quetiapine (Loebel et al., 2013a; Nasrallah et 
al., 2013), lurasidone was associated with significantly less weight gain but higher rates of akathisia, anxiety 
and EPS. For these side effects, lurasidone was similar to ziprasidone (Potkin et al., 2011), a metabolically 
friendly antipsychotic, but somnolence rates were lower with the former.  Lurasidone was associated with 
lower weight gain and metabolic disturbances than brexpiprazole (Ng-Mak et al., 2018).  
 
2.2 Bipolar depression 
 
Two studies proved lurasidone efficacious in the acute treatment of depressive episodes in bipolar disorder as 
both monotherapy (Cohen’s d value 0.51) (Loebel et al., 2014a) and adjunctive therapy to lithium or valproate 
(Cohen’s d value 0.31) (Loebel et al., 2014b). All the considered subgroups, including patients with 
subsyndromal hypomania at baseline, benefitted. Another 6-week adjunctive study with lithium or valproate  
failed to demonstrate better improvement vs. the control group at the primary 6 week endpoint; superiority 
over placebo was only confined to weeks 2-5 (Suppes et al., 2016a). However, consistently with the other two 
trials, significant improvements on measures of anxiety and health-related quality of life were maintained 
throughout. Unmeasured differences between the patient populations and/or study design differences might 
have contributed to the discrepant findings of this study.  
In a 6-months follow-up open-label study (Ketter et al., 2016), patients treated with lurasidone showed 
sustained improvement in depressive symptoms as well as in other secondary efficacy measures (Clinical 
Global Impression-Bipolar Severity of depression scale (CGI-BP-S) (Spearing et al., 1997)(Spearing et al., 
1997), Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959), Sheehan Disability Scale (SDS) (Sheehan 
et al., 1996), and Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) 
(Endicott et al., 1993)). Over 7 months, lurasidone in combination with lithium or valproate reduced the risk 
of recurrence of any mood episode but only in patients who were in a depressive phase at baseline (when 
lurasidone was initiated) (Calabrese et al., 2017).  
As with schizophrenia, lurasidone, both monotherapy and adjunctive therapy, may exhibit a linear dose-
response pattern, with greater efficacy in the 80–120 mg/d dosing range (recommended dose range 20-120 
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mg/day), based on a population dose-response analysis (Chapel et al., 2016). This holds true for both 
monotherapy and adjunctive therapy. In comparison with other treatment options for bipolar depression, a 
meta-analysis demonstrated that lurasidone monotherapy is similar in terms of likelihood to response to the 
combination olanzapine and fluoxetine, superior to quetiapine, lithium or lamotrigine (Taylor et al., 2014). 
Another study (Citrome et al., 2014a) comparing NNT, NNH and likelihood of being helped or harmed (LHH) 
for clinical response and remission concluded that lurasidone yielded benefits similar to the predecessors 
quetiapine and olanzapine-fluoxetine combination. 
The overall pattern of safety and tolerability for lurasidone in bipolar depression is consistent with that found 
in patients with schizophrenia. 
 
2.3 Major Depressive Disorder with Mixed Features 
 
The mixed-features variant is a severe form of depression characterized by the presence of at least three 
manic/hypomanic symptoms. This specifier was incorporated in the Diagnostic Statistical Manual of Mental 
Disorders 5th edition (American Psychiatric Association, 2013) . It represents an intermediate phenotype 
between major depressive disorder (MDD) and bipolar depression for which standard antidepressants may be 
ineffective or even associated with complications including suicidal ideation and behavior, manic switch, 
agitation and impulsivity (Francesca et al., 2014; Pacchiarotti et al., 2013; Sani et al., 2014; Smith et al., 2009). 
Very few treatments have been tested in this condition (Verdolini et al., 2018). Lurasidone (20-60 mg/day) 
was proved efficacious and safe to treat this condition even if only one trial is available and for this reason it 
was not included among the approved indications as of today (Suppes et al., 2016b). It significantly improved 
both depressive and manic symptoms, indicating efficacy across the range of core mood symptoms associated 
with this disorder (NNT for response and remission 3 and 4, respectively). Anxiety symptoms and patient-
reported functional impairment significantly improved as well. These clinical effects are probably due to 
lurasidone high affinity for 5-HT2A, 5-HT7 and D2 receptors at the low dosages utilized. Low dosages, 
moreover, may have contributed to good tolerability: nausea and somnolence were the two most frequently 
reported adverse events (NNH of 8 for both). Post-hoc analyses showed that lurasidone is significantly useful 
in subgroups with mild and moderate-to-severe anxiety (Tsai et al., 2017), subjects with irritability (Swann et 
al., 2017) and post-menopausal women (Sramek et al., 2017). 
 
3. Brexpiprazole 
 
Brexpiprazole is approved for the acute and maintenance treatment of schizophrenia (FDA, 2015; EMA, 2018) 
and adjunctive treatment of MDD (FDA, 2015) (Table 1). It acts as a partial agonist at 5-HT1A and D2 
receptors at similar potencies and as an antagonist at 5-HT2A and adrenergic alpha1B/2C receptors (Table 2). 
Brexpiprazole has less intrinsic agonist activity at D2 receptor than aripiprazole (Maeda et al., 2014b), the first 
7 
 
D2 receptor partial agonist available on the market, suggesting a relatively lower tendency to cause D2 partial 
agonist-mediated side effects, e.g. akathisia, insomnia, restlessness and nausea (Fleischhacker, 2005).  
Dose titration is recommended, starting from 1 mg/day. The typical titration schedule for schizophrenia is 2 
mg/day on Day 5 to Day 7, up to 4mg/day on Day 8; in MDD dosage increases are recommended at weekly 
intervals and the usually recommended target dose is 2 mg/day. 
 
3.1 Schizophrenia 
 
Brexpiprazole is efficacious in acute schizophrenia as showed by two studies (Correll et al., 2015; Kane et al., 
2015a) (Table 4). However, lower doses of brexpiprazole (2 mg) performed inconsistently between the two 
trials; therefore, the higher end of the recommended dosage range (4 mg) may be necessary. Furthermore, 
higher brexpiprazole dosage was associated with a significant improvement in PANSS-EC score and PANSS 
scores for the negative, disorganized though and uncontrolled hostility/excitement factors.  
Maintenance treatment with brexpiprazole was associated with a significantly longer time to exacerbation than 
placebo in a 52-week maintenance study (Fleischhacker et al., 2017). In the same study, brexpiprazole yielded 
significant benefit on measures of psychosocial, occupational and cognitive functioning (particularly 
attention/vigilance and visual learning). Consistently, brexpiprazole was associated with significant 
improvements in animal models of cognitive impairment associated with schizophrenia (Maeda et al., 2014a; 
Yoshimi et al., 2014; Yoshimi et al., 2015), aripiprazole, contrariwise, was not (Maeda et al., 2014a). This 
might hint at a specific advantage of brexpiprazole over aripiprazole in cognitive impairment (Citrome, 2014).  
No cognitive outcome was recorded in short-term trials and no head-to-head comparison with aripiprazole has 
been undertaken though. 
Brexpiprazole showed a good safety and tolerability profile. The only common adverse event was weight gain. 
A mean gain of ~1 kg greater than placebo was observed in short term studies. The mean change in body 
weight decreased for both brexpiprazole and placebo in the long-term. Akathisia was not significantly 
associated with brexpiprazole relatively to placebo and showed a dose-dependent pattern, occurring more 
frequently at higher doses. Most cases were mild or moderate in severity and did not result in treatment 
discontinuation. Other adverse effects such as headache, insomnia, sedation, agitation, diarrhea, nausea and 
dyspepsia were also all comparable to placebo. Effects on glucose and lipids were generally small. Minimal 
effects on prolactin were observed and no clinically relevant effects on the QTc interval were evident. 
 
3.2 Major Depressive Disorder 
 
Two studies (Thase et al., 2015a; Thase et al., 2015b) established brexpiprazole efficacy as adjunctive therapy 
to antidepressant treatment in MDD patients who failed at least one previous adequate antidepressant trial, 
with a pooled NNT of 12 (95% CI 8-26) (Citrome, 2015b) (Table 4). Brexpiprazole may be particularly useful 
in patients requiring a sedative pharmacological profile, such as patients with irritability (Fava et al., 2017) 
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and anxious distress (Hobart et al., 2018). Lastly, adjunctive brexpiprazole improved physiologic measures of 
sleep and daytime alertness in patients with inadequate response to antidepressant treatment and sleep 
disturbances (Krystal et al., 2016).  
The overall safety and tolerability profile for adjunctive brexpiprazole was mainly consistent with what 
described in patients with schizophrenia. Akathisia was more frequently reported in MDD trials compared to 
schizophrenia trials and, alongside weight gain, was recorded as common adverse reaction. 
 
4. Cariprazine 
 
Cariprazine is approved for the acute and maintenance treatment of schizophrenia (FDA, 2015; EMA, 2017) 
and for the acute treatment of manic or mixed episodes associated with bipolar I disorder (FDA, 2015) (Table 
1). It is a dopamine D3-preferring D3/D2 receptor partial agonist. Its receptor biding profile (Table 2) is similar 
to aripiprazole, except for D3 tenfold greater affinity than that for D2, so high that extremely small doses are 
sufficient to get maximal D3 occupancy (Kiss et al., 2010).  D3 receptor blockade could have pro-cognitive 
and antidepressant effects as well as potential effects on negative symptoms of schizophrenia (Gross et al., 
2013). This property is unique of cariprazine since D3 receptor occupancy is low or negligible with other 
SGAs, as reported by positron emission tomography studies (Girgis et al., 2015; Graff-Guerrero et al., 2009; 
Mizrahi et al., 2011).   
Cariprazine metabolites, desmethyl-cariprazine and didesmethyl-cariprazine, have pharmacological properties 
similar to the parental drug but didesmethyl-cariprazine half-life is considerably longer (1-3 weeks vs. 2–4 
days, approximately). Systemic exposure to didesmethyl-cariprazine is thus several times higher than that for 
cariprazine. Further characterization of didesmethyl-cariprazine is important as its long terminal half-life may 
allow the development of a once-weekly oral formulation, which could improve medication adherence. Due 
to its long-life metabolite, a missed dose of cariprazine may be associated, theoretically, with lower risk from 
sub-optimal receptor binding as compared to a drug with a shorter half-life. On the flip-side, the longer half-
life may also imply a prolonged duration of hypothetical adverse events, beyond discontinuation of treatment 
(Citrome, 2013).   
 
4.1 Schizophrenia 
 
Four trials established cariprazine efficacy in acute schizophrenia (Durgam et al., 2015a; Durgam et al., 2016b; 
Durgam et al., 2014; Kane et al., 2015b) (Table 5). Cariprazine primary asset is its action on negative symptoms. 
After a post hoc analysis suggested this therapeutic effect (Debelle et al., 2015), a double blind, randomized, 
risperidone-controlled 6 months study was designed to specifically assess cariprazine effect on negative 
symptoms. This study supported the efficacy of cariprazine as compared risperidone in the treatment of 
predominant negative symptoms of schizophrenia (Nemeth et al., 2017). The separation between the two drugs 
emerged only after 14 weeks, which is significantly later than in studies in patients with acute, positive 
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symptoms, implying a potentially different mechanism of action. Improvement in PANSS total and positive 
subscale scores was similar between cariprazine and risperidone. Furthermore, the superiority of cariprazine 
over placebo and aripiprazole in improving PANSS-factor score for negative symptoms (PANSS-FSNS) 
emerged in post-hoc analyses of data pooled from two randomized, double-blind, placebo- and active-
controlled studies in patients with acute schizophrenia with moderate/severe negative symptoms and no 
predominance of positive symptoms. The benefit of cariprazine on negative symptoms was at least partially 
independent from improvements in positive symptoms and EPS (Earley et al., 2018b). A meta-analysis 
confirmed this specific domain of efficacy (Corponi et al., 2017) and it also suggested that young patients with 
a relatively short history of disease may benefit the most from cariprazine. However, this meta-analysis 
included short-term studies which are more likely to capture secondary negative symptoms, i.e. a consequence 
of positive symptoms, depression or antipsychotics side effects. Hostility is another symptom domain targeted 
by cariprazine, as found by post-hoc analyses of the three positive trials (Citrome et al., 2016). Notably, this 
effect was partially independent from PANSS positive symptom items and independent from sedation. On the 
flipside, the impact on acute positive symptoms appears modest in comparison to other SGAs such as 
risperidone and olanzapine (Corponi et al., 2017). 
Cariprazine is also a viable option for long-term treatment as showed by a 26- to 72-week study  investigating 
time to first relapse in schizophrenia (Durgam et al., 2016a). Furthermore, a 6-months, risperidone-controlled 
study  ascertained that cariprazine was significantly more efficacious than risperidone in improving PANSS-
FSNS over 26 weeks in patients with predominantly negative symptoms (Nemeth et al., 2017).  
Overall, cariprazine was safe and well tolerated. In a pooled post-hoc analysis (Earley et al., 2017), common 
adverse events with cariprazine were EPS and akathisia. A dose-response relationship was observed for 
akathisia and overall EPS. Small increases in mean body weight (~1 to 2 kg) versus placebo were observed. 
On the plus side, cariprazine does not elicit changes in metabolic parameters or prolactine levels and it does 
not prolong the QTc interval. Another noteworthy safety consideration is the low tendency to produce sedation 
and somnolence. Tolerability data over longer periods of time were similar to those observed in the 6-week 
trials (Durgam et al., 2015a; Durgam et al., 2016a; Durgam et al., 2016b; Durgam et al., 2014; Kane et al., 
2015b; Nemeth et al., 2017). 
 
4.2 Manic or mixed episodes 
 
Three trials demonstrated cariprazine efficacy in adult patients with acute manic or mixed episodes associated 
with bipolar I disorder, with significantly higher response and remission rates compared to placebo 
[FC-f2](Calabrese et al., 2015; Durgam et al., 2015b; Sachs et al., 2015). Importantly, improvement in manic 
symptoms was not associated with worsening depressive symptom or emerging depressive episodes (Earley 
et al., 2018a). In post hoc analyses (Vieta et al., 2015), statistically significant differences in favor of 
cariprazine over placebo were observed on every item of the Young Mania Rating Scale (YMRS) (Young et 
al., 1978), effect sizes being quite robust (Cohen’s d range, 0.31-0.55). The impact was strongest on the 
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irritability item, which is an important aspect since many patients with acute mania have irritability as a 
predominant presenting feature (American Psychiatric Association, 2013). The safety profile in acute manic 
or mixed episodes matches the findings reported by studies in patients with schizophrenia. No new safety or 
tolerability concern emerged in a 16-week open-label study (Ketter et al., 2018).  
 
5. Lumateperone 
 
Lumateperone is a first-in-class drug providing selective and simultaneous modulation of serotonin, dopamine 
and glutamate. It is in the approval phase for schizophrenia and in phase III clinical development for the 
treatment of bipolar depression and agitation associated with dementia, including Alzheimer’s disease. 
Lumateperone is a high-affinity 5-HT2A receptor antagonist, having 60-fold higher affinity for these receptors 
compared to D2 receptors. As the dose is increased, it acts at D2 receptors as a presynaptic partial agonist and 
post-synaptic antagonist with functional mesolimbic and mesocortical selectivity. In addition, lumateperone 
acts as inhibitor at serotonin transporter and increases phosphorylation of glutamatergic N-methyl-D-aspartate 
(NMDA) GluN2B receptors in a mesolimbic-specific manner (Snyder et al., 2015). These unique 
pharmacological features predict enhancement of sleep and reduction of agitation and aggression at lower 
doses, antipsychotic and antidepressant efficacy at higher doses. Three clinical trials evaluated lumateperone 
in acute schizophrenia (ClinicalTrials.gov identifiers: NCT01499563, NCT02282761 and NCT02469155). 
NCT02469155 reported negative results and an unusually high placebo response was observed in this study (-
15.1 points change from baseline on PANSS total score in contrast to -7.4 points in NCT01499563 and -10.3 
points in NCT02282761). In the other two studies (NCT01499563 and NCT02282761) lumateperone 60 
mg/day demonstrated statistically significant superiority over placebo, while lumateperone 120 mg/day did 
not (NCT02282761), supposedly due to the higher frequency of somnolence/sedation. In preplanned and post-
hoc subgroup analyses lumateperone 60 mg was associated with significant improvement across a broad range 
of symptoms including general psychopathology, depressive symptoms and measures of social function. 
Moreover, cognition enhancement may be anticipated since lumateperone increases glutamatergic 
transmission, but this was still not evaluated in patients with schizophrenia. Thus, based on the 
pharmacodynamic profile of this drug and preliminary clinical data, depressive and negative symptoms as well 
as cognition may be the specific domains of lumateperone action. Specifically designed trials are needed to 
test this hypothesis.  
Lumateperone showed good tolerability with a safety profile similar to placebo for motor disturbances, 
prolactin changes, weight gain, cardiovascular and metabolic side effects. Sedation/somnolence was a common 
adverse event. Data on longer-term safety and tolerability are not available.  
Trials evaluating lumateperone in bipolar depression are currently in the recruitment phase. 
 
5. Discussion 
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SGAs represent valid alternatives to first generation antipsychotics with similar efficacy but different side 
effect profiles and different action on specific symptom domains. The first developed SGAs were characterized 
by reduced risk of extrapyramidal side effects, reduced sedation, and less prolactin dysfunction (Solmi et al., 
2017). However, the challenge was to address other relevant adverse effects, i.e. weight gain and metabolic 
syndrome, and to improve negative symptoms and cognitive deficits (Pompili et al., 2017). The novel SGAs 
discussed in this review were developed to address these unmet needs. Appreciating their efficacy/safety 
features is of great importance in the clinical practice in order to identify the specific subsets of patients that 
may benefit the most from these medications. The present paper mainly drew from indirect comparisons as 
well as pre-clinical data to outline the overall place in psychiatric pharmacotherapy for each of the novel SGAs.  
Appropriately designed head-to-head clinical trials will be necessary to fully appreciate and accurately 
establish the extent to which such agents are endowed with specific domains of efficacy and drawbacks as 
compared to other therapeutic options. 
Lurasidone was among the 15 antipsychotics for acute schizophrenia evaluated in the most comprehensive 
meta-analysis to date (Leucht et al., 2013). It had the lowest risk for ECG abnormalities and was one of only 
three agents (along with haloperidol and ziprasidone) with placebo-like effects on weight. While PANSS total 
improvement may not be outstanding in comparison to other SGAs, potential for prominent positive symptoms 
(Potkin et al., 2016), cognitive enhancement (Potkin et al., 2011) and depressive symptoms improvement 
(Nasrallah et al., 2015) make lurasidone appropriate for patients where such aspects are of clinical relevance. 
As suggested by NNH, the tolerability profile is good, with somnolence, akathisia, nausea, parkinsonism and 
insomnia (Sanford, 2013) being the most frequent adverse events. The starting dose falls at the bottom of the 
recommended therapeutic range, titration might nonetheless be needed since a dose-dependent efficacy 
gradient was observed (Kay et al., 1987; Loebel et al., 2016). However, dose increases are associated with 
higher risk of akathisia and EPS. Lurasidone is also in the pharmacologic armamentarium for mood disorders: 
monotherapy or combination therapy with lithium or valproate is recommended as a first-line treatment for 
acute bipolar depression, according to the most recently updated guidelines, issued by the Canadian Network 
for Mood and Anxiety Disorders (Yatham et al., 2018). Prior to lurasidone, the FDA-approved arsenal for 
bipolar depression was limited to quetiapine and olanzapine-fluoxetine combination, while at present only 
quetiapine is EMA-licensed for this condition. Albeit widely used in the clinical practice (Baldessarini et al., 
2007), not only do antidepressants show flimsy evidence of efficacy in bipolar depression but they may also 
be detrimental in terms of switch to mania/hypomania, rapid cycling, suicidal behavior (Pacchiarotti et al., 
2013). Antidepressants shortcomings in bipolar depression likely reflect physiopathological underpinnings 
different from the ones of unipolar depression. Of interest, lurasidone is a good fit for one current theory which 
postulates that, unlike unipolar depression, norepinephrine reuptake and 5-HT1A agonism are heavily 
implicated as core deficits in bipolar depression (Fountoulakis et al., 2015). Lastly, preliminary evidence 
provided by one trial demonstrated that lurasidone is efficacious and safe in MDD with mixed features (Suppes 
et al., 2016b). 
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Brexpiprazole and cariprazine, along with aripiprazole, belong to the D2 receptor partial agonists. These agents 
allow to obtain clinical efficacy while minimizing dopamine-related adverse events, through the  maintenance 
of a partial activation threshold that mimics the natural tonic dopamine signal in the brain (Lieberman, 2004). 
Although all three agents are dosed once daily, only for aripiprazole the recommended starting dose is the 
same as the recommended maintenance dose in both schizophrenia and mania. For cariprazine, dose titration 
may not be needed in schizophrenia, while titration is needed when treating mania. Regarding brexpiprazole, 
titration is recommended for both schizophrenia and MDD. Availability as injectable formulation and as 
generic product currently are strong points in favor of aripiprazole. While accurately designed head-to-head 
trials are needed to conclusively establish efficacy/safety differences, some indications can be given. All three 
agents are safe and tolerable: all the NNH values for weight gain, somnolence and akathisia were >10, with 
the exception of mood disorders, where in general, akathisia was more frequently observed. Despite dopamine 
partial agonists share similar adverse events, the propensity for these varies:  for the indication of schizophrenia, 
the rank order for propensity for weight gain appears to be brexpiprazole > aripiprazole > cariprazine, for 
somnolence aripiprazole > brexpiprazole > cariprazine, and for akathisia cariprazine > aripiprazole > 
brexpiprazole (Citrome, 2015a). In terms of efficacy on specific symptom domains, brexpiprazole may target 
cognitive impairment in schizophrenia more favorably than aripiprazole, as suggested by animal models 
(Maeda et al., 2014a; Yoshimi et al., 2014; Yoshimi et al., 2015), but clinical trials using cognition as primary 
outcome are necessary to support that claim (Miskowiak et al., 2017). A meta-analysis (Romeo et al., 2018) 
reported that brexpiprazole has comparable efficacy to aripiprazole as augmentation in MDD, but a more 
anxiolytic and sedative profile (Fava et al., 2017; Hobart et al., 2018; Krystal et al., 2016). Cariprazine most 
important area of action in schizophrenia is negative symptomatology: a medium term trial specifically 
designed to assess primary negative symptoms (Nemeth et al., 2017) demonstrated superiority over risperidone 
(Nemeth et al., 2017). This feature differentiates cariprazine from aripiprazole, which did not demonstrate 
efficacy against negative symptoms (Earley et al., 2018b). This suggests that cariprazine unique D3-greater-
than-D2 affinity underlies its impact on negative symptoms, while a profile unbalanced towards D2 
antagonism primarily benefits schizophrenia positive symptoms (Gross et al., 2013). In a meta-analysis 
(Romeo et al., 2018) cariprazine had similar effect size to high-dose aripiprazole in treating mania and may 
specifically address irritability. 
Lumateperone is a first-in-class drug that selectively and simultaneously modulates serotonin, dopamine and 
glutamate. In December 2018 a New Drug Application for the treatment of schizophrenia was accepted by the 
FDA. Preliminary data suggest that depressive and negative symptoms improvement as well as cognition 
enhancement may be the hallmark of lumateperone action. Most commonly encountered adverse event was 
sedation/somnolence, while liability to EPS, prolactin changes, weight gain, cardiovascular and metabolic 
abnormalities was similar to placebo. The preliminary results with lumateperone lend support to 5-HT2A 
antagonism, lumateperone’s most prominent feature, as addressing positive, negative and affective symptoms 
of schizophrenia (Davis and Correll, 2016; Eggers, 2013).   
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In conclusion, there is no one-fits-all antipsychotic. Specific strengths and weaknesses distinguish each 
compound. Thus, in order to capitalize on the various agents optimizing the trade-off between efficacy and 
side effects burden, clinicians should be familiar with the specificity profile of novel antipsychotics and 
prescribe them accordingly to each patient’s clinical profile. The new antipsychotics discussed in this review 
have overall a good tolerability in terms of cardiometabolic side effects and risk of hyperprolactinaemia, while 
akathisia risk remains still significant with lurasidone and cariprazine and sedation/somnolence with 
lumateperone. The main domains of improved efficacy of lurasidone compared to other SGAs in schizophrenia 
treatment are represented by depressive symptoms (Nasrallah et al., 2015) and cognitive dysfunction (Potkin 
et al., 2011), whereas cariprazine specific advantage, over aripiprazole as well (Earley et al., 2018b), is against 
negative symptoms (Nemeth et al., 2017). On the other hand, lurasidone (Leucht et al., 2013) and cariprazine 
(Corponi et al., 2017) may be less effective on overall psychotic symptomatology in acute schizophrenia 
compared to other SGAs, such as risperidone and olanzapine. Animal models hint that brexpiprazole may 
address cognitive impairment in schizophrenia to a greater extent than aripiprazole (Maeda et al., 2014a; 
Yoshimi et al., 2014; Yoshimi et al., 2015). Finally, it useful to mention that personalized antipsychotic 
prescription would benefit from the use of a different nomenclature based on pharmacological domains and 
modes of action and not on drug main indication. This was recently provided by the Neuroscience-based 
Nomenclature (NbN) which helps in moving forward compared to the Anatomical-Therapeutic-Chemical 
(ATC) classification and the arbitrary first vs. second generation antipsychotic distinction. Implementing the 
NbN would provide clinicians immediate information that can guide treatment choice based on the symptoms 
domains targeted by specific pharmacological domains and modes of action (Zohar et al., 2015). 
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Table 1. Lurasidone, brexpiprazole and cariprazine clinic profile. EMA: European Medicines Agency; FDA: 
Food and Drug Administration; * incidence ≥ 5% and at least twice the rate of placebo. 
 
 
 
Approved 
indications 
Starting dose Recommended 
dose 
Specific efficacy 
domains 
Common side 
effects* 
L u
ra
sid
on
e  
Acute and 
maintenance 
treatment of 
schizophrenia (FDA, 
EMA) 
40 mg/day 
(FDA) 
 
37 mg/day 
(EMA) 
40-160 mg/day 
(FDA) 
 
37-148 mg/day 
(EMA) 
• Cognition (speed 
of processing, 
visual learning, 
working memory, 
reasoning/problem 
solving and social 
cognition) 
• Depressive 
symptoms 
• Somnolence 
• Akathisia 
• Nausea 
• Parkinsonism 
• Insomnia 
Depressive Episodes 
associated with 
Bipolar I Disorder 
(Bipolar 
Depression), as 
monotherapy and as 
adjunctive therapy 
with lithium or 
valproate (FDA) 
 
20 mg/day 
(FDA) 
20-120 mg/day 
(FDA) 
• Efficacious also if 
sub-syndromal 
hypomania at 
baseline 
 
 
Br
ex
pi
pr
az
ol
e  Acute and 
maintenance 
treatment of 
1 mg/day 
(FDA, EMA) 
2-4 mg/day 
(FDA, EMA) 
• Cognition 
(attention/vigilance, 
visual learning) 
• Weight gain 
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schizophrenia (FDA, 
EMA) 
Adjunctive therapy to 
antidepressant for the 
treatment of Major 
Depressive Disorder 
(FDA) 
 
0.5 mg/day or 1 
mg/day (FDA) 
2 mg/day (FDA) • Anxiety 
• Irritability 
C
ar
ip
ra
zi
ne
 
Acute and 
maintenance 
treatment of 
schizophrenia (FDA, 
EMA) 
 
1.5 mg/day 
(FDA, EMA) 
1.5-6 mg/day 
(FDA, EMA) 
• Negative 
symptoms 
• Hostility 
• Extrapyramidal 
symptoms 
• Akathisia 
Acute treatment of 
manic or mixed 
episodes associated 
with bipolar I 
disorder in adults 
(FDA) 
 
1.5 mg/day 
(FDA) 
3-6 mg/day 
(FDA) 
• Irritability 
 
 
Table 2. Lurasidone (a), brexpiprazole (b), cariprazine (c) pharmacokinetic and pharmacodynamic profile. 
AUC: area under the curve; Cmax: maximum concentration; CYP, cytochrome P450; Ki: inhibitor constant; 
Tmax: time to Cmax 
 
(a) 
Pharmacokinetic Profile Pharmacodynamic Profile 
Bioavailability 9-19% Receptors Ki (nM) Functional activities 
Tmax 1-3 Hours 5-HT1A 6.4 Partial agonism 
Food Administration with food 
increases the AUC and the 
Cmax approximately 2- and 3-
times approximately. At least 
350 kcal of food, regardless of 
the fat content, is 
recommended. 
5-HT2A 0.5 Antagonism 
Volume of 
distribution 
6173 L 5-HT7 0.495 Antagonism 
Protein binding >99% D2 1 Antagonism 
Breast milk 
concentrations 
Present in milk rat; it is not 
known whether this drug is 
excreted in human milk 
α2A 40.7 Antagonism 
Metabolism Hepatic by CYP3A4 α2C 10.8 Antagonism 
Elimination Primarily by hepatic 
metabolism 
H1 >1000 Antagonism 
Half-life 18 Hours M1 >1000 Antagonism 
Time to steady-
state concentration 
7 Days 
Special 
populations 
A dose adjustment is 
recommended for patients 
with moderate to severe 
hepatic/renal impairment 
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(b) 
Pharmacokinetic Profile Pharmacodynamic Profile 
Bioavailability 95% Receptors Ki (nM) Functional activities 
Tmax 4 Hours 5-HT1A 0.12 Partial agonism 
Food No effect on Cmax or AUC 5-HT2A 0.47 Antagonism 
Volume of 
distribution 
1.56 ± 0.42 L/kg following 
intravenous administartion 
 
5-HT2B 
1.9 Antagonism 
Protein binding >99% 5-HT7 3.7 Antagonism 
Breast milk 
concentrations 
Present in milk rat; it is not 
known whether this drug is 
excreted in human milk 
D2L 0.3 Partial agonism 
Metabolism Hepatic by CYP3A4 and 
CYP2D6 
D3 1.1 Partial agonism 
Elimination Primarily by hepatic 
metabolism 
α1B 0.17 Antagonism 
Half-life 91 Hours α2C 0.59 Antagonism 
Time to steady-
state concentration 
10-12 Days H1 19 Antagonism 
Special 
populations 
A dose adjustment is 
recommended for patients 
with moderate to severe 
hepatic/renal impairment 
 
(c) 
Pharmacokinetic Profile Pharmacodynamic Profile 
Bioavailability 95% Receptors Ki (nM) Functional activities 
Tmax 3-6 Hours 5-HT1A 2.6 Partial agonism 
Food No effect on Cmax or AUC 5-HT2A 18.8 Antagonism 
Volume of 
distribution 
916 L 5-HT2B 0.58 Antagonism 
Protein binding 97% 5-HT7 3.7 Antagonism 
Breast milk 
concentrations 
Present in milk rat; it is not 
known whether this drug is 
excreted in human milk 
D2 0.49 Partial agonism 
Metabolism Hepatic by CYP3A4 and 
CYP2D6 
D3 0.085 Partial agonism 
Elimination Primarily by hepatic 
metabolism 
α1A 155 Antagonism 
Half-life 2-4 Days H1 23.2 Antagonism 
Time to steady-
state concentration 
10-20 Days 
Special 
populations 
No dose adjustment is 
recommended for patients 
with mild to moderate 
hepatic/renal impairment; 
cariprazine is not 
recommended in patients with 
severe hepatic/renal 
impairment 
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Table 3. Lurasidone number needed to treat and number needed to harm for common adverse events vs placebo. MADRS: Montgomery Asberg 
Depression Rating Scale; NNH: number needed to harm; NNT: number needed to treat; ns=not significant (the 95% CI contains “infinity”); 
PANSS: Positive and Negative Syndrome Scale; *a negative NNH denotes an advantage for study medication regarding the potential harm. 
 
 
 
 
Lurasidone 
  
Dose 40 mg/day 80 mg/day 120 mg/day 160 mg/day 
Schizophrenia 
Citrome, 2012 
NNT 
(95% CI) 
Response (³30% Reduction from 
Baseline in PANSS Total Score) 
6 (5-10) 6 (5-10) 7 (5-12) 4 (3-5) 
NNH 
(95% CI) 
Akathisia 12 (9–20) 10 (8–16) 6 (5–7) 22 (ns) 
Nausea 19 (11–58) 17 (11–43) 14 (9–33) 82 (ns) 
Sedation 17 (11–38) 20 (12–52) 13 (9–26) -38 (ns)* 
Somnolence 19 (12–51) 23 (14–71) 10 (7–16) 36 (ns) 
Insomnia  67 (ns) 58 (ns) 68 (ns) -198 (ns)* 
Parkinsonism 19 (13–39) 30 (18–98) 13 (9–23) 20 (11–198) 
Weight Increase ³7% from 
Baseline 
47 (ns) 43 (ns) 70 (ns) 150 (ns) 
Dose Adjunctive 20-120 
mg/day 
Monotherapy 20-60 
mg/day 
Monotherapy 80-120 
mg/day 
Depressive Episodes 
associated with 
Bipolar I Disorder 
Citrome et al., 2014a 
NNT 
(95% CI) 
Response (³50% Reduction from 
Baseline in MADRS Total Score) 
7 (4-24) 5 (3-8) 5 (4-11) 
Remission (Final MADRS Total 
Score ≤12) 
7 (4-23) 6 (4-14) 7 (4-21) 
NNH 
(95% CI) 
Akathisia 30 (ns) 18 (10–124) 12 (8–32) 
Nausea 16 (ns) 39 (ns) 11 (6–39) 
Somnolence (hypersomnia, 
sedation, somnolence) 
19 (ns) 130 (ns) 14 (8–126) 
Insomnia 64 (ns) -29 (ns)* -58 (ns)* 
Extrapyramidal symptoms 19 (ns) 40 (ns) 16 (9-60) 
Weight Increase ³7% from 
Baseline 
42 (ns) 29 (15–52318) 5550 (ns) 
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Table 4. Brexpiprazole number needed to treat and number needed to harm for common adverse events vs placebo. MADRS: Montgomery Asberg 
Depression Rating Scale; NNH: number needed to harm; NNT: number needed to treat; ns=not significant (the 95% CI contains “infinity”); 
PANSS: Positive and Negative Syndrome Scale. 
 
 
 
 
Brexpiprazole 
  
Dose 2-4 mg/day 
Schizophrenia 
Citrome, 2015b 
NNT 
(95% CI) 
Response (³30% Reduction from Baseline in 
PANSS Total Score) 
7 (5–12) 
NNH 
(95% CI) 
Akathisia 112 (ns) 
Sedation 78 (ns) 
Weight Increase ³7% from Baseline 50 (26–1773) 
Dose 2-3 mg/day 
Adjunctive therapy to 
antidepressant for the 
treatment of Major 
Depressive Disorder 
Citrome, 2015b 
NNT 
(95% CI) 
Response (³50% Reduction from Baseline in 
MADRS Total Score) 
12 (8–26) 
Remission (Final MADRS Total Score ≤12) 21 (12–138) 
NNH 
(95% CI) 
Akathisia 15 (11–23) 
Somnolence (hypersomnia, sedation, 
somnolence) 
24 (17–42) 
Weight Increase ³7% from Baseline 22 (15–42) 
 
Table 5. Cariprazine number needed to treat and number needed to harm for common adverse events vs placebo. ND, no difference or rate with 
medication is lower than rate with placebo; NNH: number needed to harm; NNT: number needed to treat; ns=not significant (the 95% CI contains 
“infinity”); PANSS: Positive and Negative Syndrome Scale; YMRS: Young Mania Rating Scale 
 
 
 
 
Cariprazine 
  
Dose 1.5-6 mg/day 
Schizophrenia 
Citrome, 2015a 
NNT 
(95% CI) 
Response (³30% Reduction from Baseline in 
PANSS Total Score) 
10 (7-19) 
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Dose 1.5-3 mg/day 4.5-6 mg/day 
NNH 
(95% CI) 
Akathisia 20 (13–48) 12 (9–18) 
Nausea ND 50 (ns) 
Somnolence and sedation ND 34 (18–610) 
Insomnia  100 (ns) 50 (ns) 
Extrapyramidal symptoms 15 (10–31) 10 (7–15) 
Weight Increase ³7% from Baseline 50 (28–287) 100 (ns) 
Dose 3-6 mg/day 
Manic or Mixed 
Episodes Associated 
with Bipolar I 
Disorder  
Citrome, 2015a 
 
NNT 
(95% CI) 
Response (³50% Reduction from Baseline in 
YMRS Total Score) 
5 (4-8) 
NNH 
(95% CI) 
Akathisia 7 (5-9) 
Nausea 24 (12-363) 
Insomnia ND 
Extrapyramidal symptoms 15 (9-35) 
Weight Increase ³7% from Baseline ND 
 
 
